Chair
Member
Audit Committee Position

Gil Labrucherie, JD

Mr. Labrucherie brings more than 20 years of senior leadership experience in finance, legal and corporate development to the Board. Prior to serving as CFO of Nektar, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie was an executive at different organizations where he was responsible for global corporate alliances and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.

Chair

Philippe Fauchet

Mr. Fauchet has spent more than 35 years in the pharmaceutical industry, including most recently as the chairman of GlaxoSmithKline Japan where he joined as president & representative director in 2010. Previously, he served as senior vice president, corporate business development, head of Sanofi-Aventis Group and as a member of the Management Committee. Philippe is currently a director and senior advisor to several biotech companies, as well as a venture partner in an investment firm.

Member

Dr. Vlad Hogenhuis, MD

Dr. Vlad Hogenhuis, MD, joined Rezolute Bio as a board member in March 2021. He previously served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline. Earlier in his career, he served in leadership positions at Merck in the US, China, and Europe, where he was responsible for managing the P&L of specialty and cardiovascular care medicines. He also served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Center in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats and sealants. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint program of the World Health Organization and the International Agency for the Prevention of Blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands, and a M.B.A. from the Wharton School of Business at The University of Pennsylvania, Philadelphia.

Member

Audit Committee Charter

Download
Compensation, Nominating and Corporate Governance Committee Position

Philippe Fauchet

Mr. Fauchet has spent more than 35 years in the pharmaceutical industry, including most recently as the chairman of GlaxoSmithKline Japan where he joined as president & representative director in 2010. Previously, he served as senior vice president, corporate business development, head of Sanofi-Aventis Group and as a member of the Management Committee. Philippe is currently a director and senior advisor to several biotech companies, as well as a venture partner in an investment firm.

Chair

Dr. Vlad Hogenhuis, MD

Dr. Vlad Hogenhuis, MD, joined Rezolute Bio as a board member in March 2021. He previously served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline. Earlier in his career, he served in leadership positions at Merck in the US, China, and Europe, where he was responsible for managing the P&L of specialty and cardiovascular care medicines. He also served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Center in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats and sealants. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint program of the World Health Organization and the International Agency for the Prevention of Blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands, and a M.B.A. from the Wharton School of Business at The University of Pennsylvania, Philadelphia.

Member

Dr. Nerissa Kreher, MD

Dr. Kreher is a pediatric endocrinologist with more than 15 years of biotech industry experience in both Clinical Development and Medical Affairs. She has spent her career focused on drug development for patients with rare diseases in multiple therapeutic areas. Dr. Kreher is currently the Chief Medical Officer of Entrada Therapeutics where she is responsible for Clinical Development, Medical Affairs, Regulatory and Patient Advocacy. Her prior roles include Chief Medical Officer at Tiburio Therapeutics and Avrobio. Earlier in her career, she held roles of increasing responsibility at companies including Zafgen, Enobia (acquired by Alexion) and Genzyme. Dr. Kreher completed her pediatric endocrinology fellowship and pediatric residency at Riley Hospital for Children in Indianapolis, her M.D. at East Carolina University School of Medicine and her B.S. Biology from The University of North Carolina – Chapel Hill.

Member

Gil Labrucherie, JD

Mr. Labrucherie brings more than 20 years of senior leadership experience in finance, legal and corporate development to the Board. Prior to serving as CFO of Nektar, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie was an executive at different organizations where he was responsible for global corporate alliances and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.

Member

Compensation Committee Charter

Download

Nominating and Corporate Governance Committee Charter

Download

Gil Labrucherie, JD

Mr. Labrucherie brings more than 20 years of senior leadership experience in finance, legal and corporate development to the Board. Prior to serving as CFO of Nektar, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie was an executive at different organizations where he was responsible for global corporate alliances and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.

Philippe Fauchet

Mr. Fauchet has spent more than 35 years in the pharmaceutical industry, including most recently as the chairman of GlaxoSmithKline Japan where he joined as president & representative director in 2010. Previously, he served as senior vice president, corporate business development, head of Sanofi-Aventis Group and as a member of the Management Committee. Philippe is currently a director and senior advisor to several biotech companies, as well as a venture partner in an investment firm.

Dr. Vlad Hogenhuis, MD

Dr. Vlad Hogenhuis, MD, joined Rezolute Bio as a board member in March 2021. He previously served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline. Earlier in his career, he served in leadership positions at Merck in the US, China, and Europe, where he was responsible for managing the P&L of specialty and cardiovascular care medicines. He also served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Center in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats and sealants. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint program of the World Health Organization and the International Agency for the Prevention of Blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands, and a M.B.A. from the Wharton School of Business at The University of Pennsylvania, Philadelphia.

Philippe Fauchet

Mr. Fauchet has spent more than 35 years in the pharmaceutical industry, including most recently as the chairman of GlaxoSmithKline Japan where he joined as president & representative director in 2010. Previously, he served as senior vice president, corporate business development, head of Sanofi-Aventis Group and as a member of the Management Committee. Philippe is currently a director and senior advisor to several biotech companies, as well as a venture partner in an investment firm.

Dr. Vlad Hogenhuis, MD

Dr. Vlad Hogenhuis, MD, joined Rezolute Bio as a board member in March 2021. He previously served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline. Earlier in his career, he served in leadership positions at Merck in the US, China, and Europe, where he was responsible for managing the P&L of specialty and cardiovascular care medicines. He also served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Center in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats and sealants. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint program of the World Health Organization and the International Agency for the Prevention of Blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands, and a M.B.A. from the Wharton School of Business at The University of Pennsylvania, Philadelphia.

Dr. Nerissa Kreher, MD

Dr. Kreher is a pediatric endocrinologist with more than 15 years of biotech industry experience in both Clinical Development and Medical Affairs. She has spent her career focused on drug development for patients with rare diseases in multiple therapeutic areas. Dr. Kreher is currently the Chief Medical Officer of Entrada Therapeutics where she is responsible for Clinical Development, Medical Affairs, Regulatory and Patient Advocacy. Her prior roles include Chief Medical Officer at Tiburio Therapeutics and Avrobio. Earlier in her career, she held roles of increasing responsibility at companies including Zafgen, Enobia (acquired by Alexion) and Genzyme. Dr. Kreher completed her pediatric endocrinology fellowship and pediatric residency at Riley Hospital for Children in Indianapolis, her M.D. at East Carolina University School of Medicine and her B.S. Biology from The University of North Carolina – Chapel Hill.

Gil Labrucherie, JD

Mr. Labrucherie brings more than 20 years of senior leadership experience in finance, legal and corporate development to the Board. Prior to serving as CFO of Nektar, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie was an executive at different organizations where he was responsible for global corporate alliances and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.